With Prevnar 20, Pfizer Aims To Maintain A Top Franchise
The successor to Pfizer’s 13-valent pneumococcal vaccine, a lynchpin of the company's lifecycle management strategy, was approved in the US.
You may also be interested in...
The pediatric market represents 70%-75% of the market for pneumococcal vaccines; Merck & Co.'s Vaxneuvance was already approved for infants earlier this year.
Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.
Ahead of CDC advisory committee this fall, Merck highlights additional bacteria serotypes its Vaxneuvance protects against while Pfizer touts Prevnar 13’s indication for pneumonia.